Ranolazine is a new therapeutic agent clinically indicated for symptomatic relief of chronic angina pectoris for individuals already taking standard antianginal therapy. It has been shown to reduce the frequency of anginal episodes and increase exercise tolerance (5, 6,22). The mechanism of the antianginal effects of ranolzaine are uncertain but may be related to its ability to inhibit late Na~+ current (I_(Na)) (1, 21). Beyond its antianginal effects, some preclinical studies have suggested that ranolazine may also have antiarrhythmic potential. In their article, Song et al. (20a) build on their previous investigations with ranolazine and its potential for antiarrhythmic activity.
展开▼
